Answer
In wet age-related macular degeneration studies, the most frequently reported adverse reactions to brolucizumab were reduced visual acuity (7.3%), cataract (7.0%), conjunctival haemorrhage (6.3%) and vitreous floaters (5.1%).
Sources for this answer
- Beovu 120 mg/ml solution for injection in pre filled syringeNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked